Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Etoposide phosphate: what, why, where, and how?

L Schacter1

  • 1Department of Medicine, Yale Cancer Center, New Haven, CT 06520, USA.

Seminars in Oncology
|December 1, 1996
PubMed
Summary

Etoposide phosphate is a water-soluble prodrug of etoposide, offering improved formulation for cancer treatment. It provides identical efficacy and pharmacokinetics to etoposide with enhanced administration flexibility.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reengineering a database for clinical trials management: lessons for system architects.

Controlled clinical trials·2000
Same author

Managing attribute--value clinical trials data using the ACT/DB client-server database system.

Journal of the American Medical Informatics Association : JAMIA·1998
Same author

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1996
Same author

Phase I and pharmacokinetic study of etoposide phosphate.

Anti-cancer drugs·1995
Same author

Phase II study of elsamitrucin in non-small cell lung cancer.

Investigational new drugs·1994
Same author

A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1992

Area of Science:

  • Oncology
  • Pharmacology
  • Drug Development

Background:

  • Podophyllotoxin derivatives, etoposide and teniposide, are effective chemotherapy agents derived from plant extracts.
  • Etoposide, while widely used for various cancers, suffers from poor water solubility, limiting its administration.
  • Podophyllum peltatum has a historical use as a folk remedy and was recognized for its anti-cancer properties.

Purpose of the Study:

  • To introduce etoposide phosphate as a water-soluble prodrug of etoposide.
  • To highlight the advantages of etoposide phosphate over conventional etoposide formulations.
  • To compare the pharmacokinetic, toxicity, and clinical activity profiles of etoposide and etoposide phosphate.

Main Methods:

  • Etoposide phosphate (Etopophos) was developed as a water-soluble prodrug.
  • Intravenous administration of etoposide phosphate was studied.
  • Pharmacokinetic, toxicity, and clinical activity were assessed and compared to etoposide.

Main Results:

  • Etoposide phosphate is rapidly and completely converted to etoposide after intravenous dosing.
  • The pharmacokinetic profile, toxicity, and clinical activity of etoposide phosphate are identical to etoposide.
  • Etoposide phosphate's water solubility allows for flexible administration, including bolus injections and continuous infusions, without common formulation additives.

Conclusions:

  • Etoposide phosphate offers an improved formulation of etoposide with enhanced usability.
  • The prodrug maintains the therapeutic efficacy and safety profile of etoposide.
  • Water solubility significantly improves the administration options for etoposide-based chemotherapy.

Related Experiment Videos